glp-1 in the brain Glucagon-like Peptide-1 Receptor Agonists: Possible Panacea? Frontiers | The mechanism and

: Intestinal resection

Yates and J

A 2021 research review concluded that oral semaglutide is as effective, if not more so, than injectable versions in reducing A1C levels in people with diabetes

Glossary CLBP chronic low back pain CKD chronic kidney disease CNS central nervous system CV cardiovascular CVD cardiovascular disease FDA Food and Drug Administration GLP-1 glucagon-like peptide-1 GLP-1s glucagon-like peptide-1 receptor agonists HF heart failure HTN hypertension MACE major adverse cardiovascular events MASH metabolic dysfunction-associated steatohepatitis OA osteoarthritis OSA obstructive sleep apnea PAD peripheral arterial disease SC subcutaneous SGLT2i sodium-glucose co-transporter 2 inhibitor sNDA supplemental New Drug Application T1DM type 1 diabetes mellitus T2DM type 2 diabetes mellitus U.S